» Articles » PMID: 19042019

Prognostic Value of CXCR4 and FAK Expression in Acute Myelogenous Leukemia

Overview
Journal Leuk Res
Date 2008 Dec 2
PMID 19042019
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

We analysed, by flow cytometry, the "adhesive" phenotype of acute myelogenous leukemia (AML) cells from 36 patients treated in our institution. In univariate analysis, the main prognostic factor for CR achievement was lower CXCR4 expression (p=0.03). Overall survival (OS) was negatively influenced by higher CXC chemokine receptor 4 (CXCR4) (p=0.01), very late antigen-4 (VLA-4) (p=0.01), and focal adhesion kinase (FAK) expression (p=0.04). Combination of these markers allowed to distinguish two prognostic groups: patients overexpressing 2 or 3 factors had a significantly shorter OS (p=0.015). CXCR4, VLA-4 and FAK are new phenotypic markers which could be helpful to establish risk-stratified therapeutic strategies.

Citing Articles

MiR-133 promotes the multidrug resistance of acute myeloid leukemia cells (HL-60/ADR) to daunorubicin.

Liu L, Yu K, Yu J, Tao W, Wei Y Cytotechnology. 2024; 76(6):833-846.

PMID: 39435426 PMC: 11490624. DOI: 10.1007/s10616-024-00656-9.


Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence.

Capasso G, Mouawad N, Castronuovo M, Ruggeri E, Visentin A, Trentin L Front Oncol. 2024; 14:1446723.

PMID: 39281374 PMC: 11392731. DOI: 10.3389/fonc.2024.1446723.


The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate.

Klement L, Drube J Front Oncol. 2023; 13:1258679.

PMID: 37849810 PMC: 10577206. DOI: 10.3389/fonc.2023.1258679.


One-Chip Isolation of Drug-Resistant Acute Myeloid Leukemia Cells with CXCR4-Targeted Magnetic Fluorescent Nanoprobes.

Wang F, Jiang Y, Wang L, Chen Y, Zhang Y, Ma M Nanomaterials (Basel). 2022; 12(10).

PMID: 35630929 PMC: 9142899. DOI: 10.3390/nano12101711.


A biomimetic nanocomposite with enzyme-like activities and CXCR4 antagonism efficiently enhances the therapeutic efficacy of acute myeloid leukemia.

Kong F, He H, Bai H, Yang F, Ma M, Gu N Bioact Mater. 2022; 18:526-538.

PMID: 35415298 PMC: 8976099. DOI: 10.1016/j.bioactmat.2022.03.022.